AVNS vs. WRBY, LIVN, ENOV, NVCR, TMDX, LMAT, TNDM, SLNO, CNMD, and CDRE
Should you be buying Avanos Medical stock or one of its competitors? The main competitors of Avanos Medical include Warby Parker (WRBY), LivaNova (LIVN), Enovis (ENOV), NovoCure (NVCR), TransMedics Group (TMDX), LeMaitre Vascular (LMAT), Tandem Diabetes Care (TNDM), Soleno Therapeutics (SLNO), CONMED (CNMD), and Cadre (CDRE). These companies are all part of the "medical equipment" industry.
Avanos Medical vs.
Avanos Medical (NYSE:AVNS) and Warby Parker (NYSE:WRBY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends, valuation and community ranking.
Avanos Medical has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Warby Parker has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500.
Avanos Medical has a net margin of 2.30% compared to Warby Parker's net margin of -4.39%. Avanos Medical's return on equity of 4.70% beat Warby Parker's return on equity.
Avanos Medical received 46 more outperform votes than Warby Parker when rated by MarketBeat users. Likewise, 55.84% of users gave Avanos Medical an outperform vote while only 42.11% of users gave Warby Parker an outperform vote.
Warby Parker has a consensus price target of $21.92, indicating a potential downside of 8.76%. Given Warby Parker's stronger consensus rating and higher probable upside, analysts clearly believe Warby Parker is more favorable than Avanos Medical.
In the previous week, Warby Parker had 1 more articles in the media than Avanos Medical. MarketBeat recorded 9 mentions for Warby Parker and 8 mentions for Avanos Medical. Avanos Medical's average media sentiment score of 0.80 beat Warby Parker's score of 0.54 indicating that Avanos Medical is being referred to more favorably in the media.
Avanos Medical has higher earnings, but lower revenue than Warby Parker. Warby Parker is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks.
95.2% of Avanos Medical shares are owned by institutional investors. Comparatively, 93.2% of Warby Parker shares are owned by institutional investors. 2.9% of Avanos Medical shares are owned by insiders. Comparatively, 26.5% of Warby Parker shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Avanos Medical beats Warby Parker on 10 of the 18 factors compared between the two stocks.
Get Avanos Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVNS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avanos Medical Competitors List
Related Companies and Tools
This page (NYSE:AVNS) was last updated on 2/22/2025 by MarketBeat.com Staff
